ISABEL MANUELA
ÁLVAREZ LÓPEZ
Instituto Valenciano de Oncologia
Valencia, EspañaInstituto Valenciano de Oncologia-ko ikertzaileekin lankidetzan egindako argitalpenak (13)
2023
-
Long-term outcomes of high-risk HR-positive and HER2-negative early breast cancer patients from GEICAM adjuvant studies and El Álamo IV registry
Breast Cancer Research and Treatment, Vol. 201, Núm. 2, pp. 151-159
2022
2021
2019
-
Phase III evaluating the addition of fulvestrant (F) to anastrozole (A) as adjuvant therapy in postmenopausal women with hormone receptor-positive HER2-negative (HR+/HER2−) early breast cancer (EBC): results from the GEICAM/2006–10 study
Breast Cancer Research and Treatment, Vol. 177, Núm. 1, pp. 115-125
-
SEOM clinical guidelines in advanced and recurrent breast cancer (2018)
Clinical and Translational Oncology, Vol. 21, Núm. 1, pp. 31-45
2018
-
Outcomes of single versus double hormone receptor–positive breast cancer. A GEICAM/9906 sub-study
European Journal of Cancer, Vol. 94, pp. 199-205
-
Prognostic role for the derived neutrophil-to-lymphocyte ratio in early breast cancer: a GEICAM/9906 substudy
Clinical and Translational Oncology, Vol. 20, Núm. 12, pp. 1548-1556
2017
-
A definition for aggressive disease in patients with HER-2 negative metastatic breast cancer: an expert consensus of the Spanish Society of Medical Oncology (SEOM)
Clinical and Translational Oncology, Vol. 19, Núm. 5, pp. 616-624
2015
-
SEOM clinical guidelines in metastatic breast cancer 2015
Clinical and Translational Oncology, Vol. 17, Núm. 12, pp. 946-955
2013
-
Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high-risk, node-negative breast cancer: Results from the GEICAM/2003-02 study
Journal of Clinical Oncology
-
SEOM clinical guidelines for the management of metastatic breast cancer 2013
Clinical and Translational Oncology, Vol. 15, Núm. 12, pp. 1004-1010
2010
-
SEOM clinical guidelines for the treatment of metastatic breast cancer
Clinical and Translational Oncology, Vol. 12, Núm. 11, pp. 719-723
2008
-
Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by paclitaxel for early breast cancer
Journal of the National Cancer Institute, Vol. 100, Núm. 11, pp. 805-814